Slide 1: Intimation of Analysts/Investors Virtual Conference Meeting
Date: November 26, 2021 To, BSE Limited National Stock Exchange of India Ltd. Phiroze Jeejeebhoy Towers, Exchange Plaza, Plot no. C/1, G Block, Dalal Street, Bandra-Kurla Complex, Bandra (E), Mumbai - 400 001 Mumbai - 400 051 Scrip Code: 531599 Symbol: FDC Subject: Intimation of Schedule of Analysts
Slide 2: Company Secretary signature and notice
The above scheduled meeting shall be subject to changes in case of exigencies, if any. Kindly take the above information on record. For FDC Limited Digitally signed by VARSHARANI VARSHARANI RAJARAM KATRE RAJARAM KATRE Date: 2021.11.26 18:37:22 +05'30' Varsharani Katre Company Secretary & Compliance
Slide 3: FDC Limited Investor Presentation
FDC LIMITED Investor Presentation www.fdcindia.com FDC
Slide 4: Disclaimer
DISCLAIMER This report may contain certain statements that might be considered forward looking. These statements are subject to certain risk and uncertainties, since they are based on certain assumptions and expectations of future events. Actual results may differ materially from those expressed in
Slide 5: Strong Domestic Business
x ve Strong Domestic Business . Multiple levers, high growth brands to anchor growth . Zifi- Category Creator in CEFIXIME . Electral - Category creator & sustained leader in Oral Rehydration Salts . Ophthalmology: legacy strength — 3rd highest in volumes . Strong portfolio of functional foods & ener
Slide 6: Revenue mix and sales
Revenue Mix Export 13% | Source: Internal Data H1FY22 Domestic 87% = ANTI-INFECTIVES = GASTRO INTESTINAL = VMN = DERMA = OPHTHAL = CARDIAC @ ANTIVIRAL = GYNAEC. = RESPIRATORY = OTHERS Domestic Secondary sales lm Val Cr ill % Growth 1460 1494 ‘267 1368 MATSEP'17 — MATSEP'18 = MATSEP'19. = MATSEP'20.—
Slide 7: Multiple Top Brands to anchor growth
Multiple Top Brands to anchor growth Brand Molecule Rank Rs. Crs MS % Zifi Cefixime @ 284 24.8 Electral Oral Rehydration (1) 283 70.1 Enerzal Energy Drink @ 113 42.2 Zifi CV Cefixime + Clavulanic acid (1) 54 40.1 Zocon Tab Fluconazole (1) 53 26.7 Amodep AT | Atenolol + Amlodipine (4) 47 7.7 Zathrin
Slide 8: Zifi - Category Leader in Cefixime
CFDQ) | ziti - category Leader in CEFIXIME Zifi — Consistent Category Leader In an otherwise fragmented market (Market Share) (Market Shares of Other Players) 24.0% 23.9% 24.8% & Market Share in 2019 21.6% 22:5% m@ Market Share in 2021 5.7% 5.8% 5.7% 5.4% 5.3% 4.0% 2019 2020 2021 TAXIM-O MAHACEF OMN
Slide 9: Electral - Brand synonymous with product category
Electral -Brand synomous with product category lectral — Category Creator & Consistent Leader in Oral Rehydration Salts (WHO Formula) In an otherwise fragmented market (Market Share) (Market Shares of Other Players) 72.6% @ Market Share in 2019 70.4% 70.1% & Market Share in 2021 13.8% 13.3% 4.1% 2.3
Slide 10: Enerzal - Category Leader in Energy Drinks
EDO Enerzal— Category Leader in Energy Drinks Enerzal — Consistent Category Leader In an otherwise fragmented market (Market Share) (Market Shares of Other Players) 46.4% & Market Share in 2019 44.3% 42.2% 32.2% 49 cop 2019 2020 2021 ORSL ORSL PLUS HEALTH OK — ELECTROKIND-L Player Rank 5 Fig ERZAY P
Slide 11: Zifi CV - Category Leader in Cefixime and Clavulanate
Zifi CV — Category Leader in Cefixime and Clavulanate Potassium Combination Zifi CV- Consistent Category Leader In an otherwise fragmented market (Market Share) (Market Shares of Other Players) & Market Share in 2019 @ Market Share in 2021 38.1% 36.1% 10.8% 9.9% 9.8% 3.8% 7.0% 5.7% 5.5% 2019 2020 20
Slide 12: Ophthalmology - Legacy Strength
Rank by Value a oon DH BF WN PR 10 ALLERGAN INDIA LTD AJANTA PHARMA LTD SUN + RANBAXY CIPLA LTD NOVARTIS + ALCON ENTOD MICRO INTAS SUNWAYS FDC Limited Timolol Stans a7 | (aa Lp ext — Ophthalmology — Legacy Strength Rank by Volume CT u F&F WN PR CIPLA ALLERGAN INDIA LTD FDC Limited AJANTA Pharma SUN
Slide 13: AWACS Highlights - MAT Sept 2021
AWACS Highlights — MAT Sept 2021 ¢ As per MAT Sept 2021: v FDC’s Value growth stands at 22.2% against a market growth of 15.2%. Y FDC’s Volume growth stands at 16.6% against a market growth of 7.1%. * FDCis ranked the 5‘ fastest growing company, among the top 25 corporates, in terms of Value. ¢ Inte
Slide 14: New Launches in FY21
| New Launches in FY21 Covid-19 Special Launches ILA Faviplrayr Tablets 209 mg my: Other Launches Ceftriaxone Iecton IP figicF| Bilastine Tablets 20 mg ATA’ wie 12
Slide 15: Manufacturing Facilities & Regulatory Highlights -1
© | Manufacturing Facilities & Regulatory Highlights -1 ¢ Sterile ophthalmic preparations Ophthalmic facility is MHRA GMP approved, @ Oral Liquid Undergone 7 MHRA inspections between elite iter 2003 and Sep 2021. Recent virtual inspection ® Oral Rehydration Salts was completed between Sep 6-9, 2021
Slide 16: Manufacturing Facilities & Regulatory Highlights -2
DO) Manufacturing Facilities & Regulatory Highlights -2 % Oral Solid Dosages (Tablet) @ MHRA GMP approved; last MHRA inspection in Sep 2019 @ cGMP Compliant by PIC’s Malaysia. Last inspection in May 2017 @ Active Pharmaceutical @ USFDA approved Ingredients (APIs) WHO @ CEP 2 14
Slide 17: Manufacturing Facilities & Regulatory Highlights -3
— Manufacturing Facilities & Regulatory Highlights -3 u ai A % Oral Rehydration Salt WHO, Unicef, Tanzania, Ethiopia, ‘ @ Food Plant Malawi ® FSSAI, BIS. @ Ready to drink — Energy drink @ Certified ISO 22000:2005-Food Safety @ Nutraceuticals Management System. % Protein supplements, Spray dried infa
Slide 18: Top Countries for Export Sale of APIs & Formulations
EDO TOP 10 Countries for Export Sale of APIs & Formulations Export Formulation Sales H1FY22 Export API Sales HiFY22 a @ Japan a m Germany @ Ethiopia ; @ New Zealand = Taiwan @ Nepal ™@ Bangladesh @ Hong Kong ™ South Korea Chile @ Turkey @ Malaysia m UAE Srilanka Algeria m Myanmar H Australia @ Other
Slide 19: Sales and YoY Growth %; EBITDA Margin and EPS
Sales (in crs) and YoY Growth % 45% Q3FY20 Q4FY20 Q1FY21 Q2FY21 Q3FY21 Q4FY21 Q1FY22 Q2FY22 mmm Sales (in Crs) YOY Sales Growth % EBITDA Margin and EPS 43% 33% 34% 4.26 5.36 2.49 Q3FY20 Q4FY20 Q1FY21 Q2FY21 Q3FY21 Q4FY21 QUFY22 Q2FY22 Mmm EPSinRs ——EBITDA % Source: Internal Data 17
Slide 20: Half Yearly Performance
Half Yearly Performance in crs. (except RPS) H1iFY22 H1FY20 YoY % Revenue from operations 841.25 681.63 23% Other income 54.01 46.74 16% Total Income 895.26 728.37 23% Operating Expenses 655.06 470.49 39% EBITDA 240.20 257.87 -7% Finance Cost 1.52 1.57 -3% Depreciation 18.93 19.01 0% Profit before T
Slide 21: Financial Summary - Year Scenario
| Financial Summary — 5 Year Scenario Figures in INR Crores FY17 FY18 FY19 FY20 FY21 Total Sales 1,046 | 1,070 1,076 1,323 1,316 Domestic Sales 883 926 902 1,064 993 International Sales 163 144 173 259 323 Sales Growth 5% 2% 0.55% 23% -0.53% Operating Expenditure 804 851 856 1,048 1,001 EBITDA 292 2
Slide 22: Best in Class Operating Financials
EDO Best in Class Operating Financials Core RoE % Working Capital Days 68 38% 39% 61 60 7 T i \) I I | ™Mar-17. ™Mar-18 m™Mar-19 ™@Mar-20 m Mar-21 ™Mar-17 @Mar-18 ™Mar-19 @& Mar-20 m Mar-21 Book Value (Rs) Free Cash Flow per share (Rs) 14.04 a0 102 7 a i ' ci ™Mar-17 ™Mar-18 m™ Mar-19 ™@Mar-20 mi Ma
Slide 23: For updates and company information, please visit our website
For updates and company information, please visit our website i.e. www.fdcindia.com For specific queries, kindly email on investors@fdcindia.com 21
Slide 24: Thank You!
@ Thank You! 22